|Bid||0.00 x 800|
|Ask||0.00 x 1000|
|Day's range||49.50 - 50.76|
|52-week range||49.35 - 127.20|
|Beta (5Y monthly)||1.02|
|PE ratio (TTM)||9.06|
|Earnings date||04 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||85.71|
DENVER, September 21, 2021--Shuamn, Glenn & Stecker investigates Emergent BioSolutions, Inc. (NYSE: EBS).
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Emergent (EBS) is set to provide manufacturing services for doses of Providence Therapeutics' COVID-19 vaccine candidate as well as for its bulk drug substance.